COMP <GO>
APMD vs SGMT // EV/EBITDA & P/E VALUATION
Apnimed Inc. (NASDAQ) VS. Sagimet Biosciences Inc. (Series A) (NASDAQ) • 15-METRIC TALLY: APMD 0
— SGMT 2
■ METRIC PARITY
LAST: $17.34 (-9.45%) • MKT CAP: $721.9M
valuation
—
LAST: $10.43 (-2.89%) • MKT CAP: $735.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APMD VS. SGMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APMD | SGMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -6.21% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 53.2 | -17.84 | SGMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $721.9M | $735.7M | -$13.8M | SGMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APMD REV | SGMT REV | APMD GROSS % | SGMT GROSS % | APMD FCF | SGMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$45.6M |
| FY 2024 | — | $0 | — | — | — | -$42.4M |
| FY 2023 | — | $2.0M | — | — | — | -$23.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APMD // BETA —
SGMT // BETA —